Mira Pharmaceuticals shared preclinical weight loss data for its candidate SKNY-1. The results come from mouse studies, not human trials.
Recap by typeshit. Full story at StreetInsider.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
Researchers suggest Ozempic and Wegovy could influence hiring decisions and workplace productivity as more Americans take them.
Michigan State's Jamie Alan calls the move dangerous, while the Alliance for Pharmacy Compounding says licensed pharmacies beat gray-market vials.
Loading…